EMA lists rare spinal condition as side effect of AstraZeneca vaccine

Reuters.- A European medicines regulator safety panel on Friday recommended adding a rare spinal inflammation called transverse myelitis as a side effect to AstraZeneca’s Covid-19 vaccine.

The vaccine has faced several setbacks, such as delays in production and probing of regulatory bodies after rare cases of serious side effects such as blood clots with low platelets, which led several countries to restrict or stop its use.

The European Medicines Agency (EMA) safety committee also reiterated its recommendation to include a similar warning for Johnson & Johnson’s single-dose vaccine.

Transverse myelitis is characterized by inflammation of one or both sides of the spinal cord and can cause weakness in the arms or legs, sensory symptoms or problems with bladder or bowel functions.

The committee, after reviewing the data, concluded that a causal relationship between these two vaccines and transverse myelitis is at least a reasonable possibility. However, he added that the benefit-risk profile of both vaccines has not changed.

AstraZeneca did not immediately respond to a Reuters request for comment.

The regulatory agency did not provide information on how many such cases have been reported after administration of the vaccine, but said that transverse myelitis has been added as an adverse reaction of unknown frequency to the product information of the vaccines.

Reports of a serious neurological disease were also the reason for the interruption of early-stage trials of vaccines from AstraZeneca and J&J, which are based on similar technology.

Follow the information on business and news in Forbes Mexico

The regulatory body also recommended updating the information on AstraZeneca vaccine product, in relation to rare blood clots occurring after the first dose, to say that fewer such side effects were seen after the second dose.

Among the 1,809 cases of the condition called thrombosis with thrombocytopenia syndrome reported worldwide, it said 1,643 were reported after the first dose and 166 after the second.

Follow us on Google News to always stay informed

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button

Adblock Detected

Please consider supporting us by disabling your ad blocker